Sibley Margaret H, Flores Sabrina, Murphy Madeline, Basu Hana, Stein Mark A, Evans Steven W, Zhao Xin, Manzano Maychelle, van Dreel Shauntal
University of Washington School of Medicine, Seattle, WA, USA.
Seattle Children's Research Institute, Seattle, WA, USA.
J Child Psychol Psychiatry. 2025 Jan;66(1):132-149. doi: 10.1111/jcpp.14056. Epub 2024 Oct 6.
Attention Deficit/Hyperactivity Disorder (ADHD) demonstrates unique developmental manifestations in adolescence with implications for optimized, age-appropriate treatment. This 10-year update is the third in a series of systematic reviews examining the efficacy and safety of adolescent ADHD treatments. We broadly examined efficacy on ADHD symptoms, impairments, and other reported outcomes. Acute and long-term efficacy, and treatment moderators, were considered.
We performed PubMed, EMBASE, and PsycINFO searches for articles published or in press from 2013 to 2024, integrated with hand search and randomized controlled trials (RCTs) identified in this series' earlier reviews. RCTs examining the safety or efficacy of interventions delivered to adolescents (ages 10.0-19.9) with a diagnosis of ADHD were included. Study characteristics were extracted and reviewed, quality of evidence was assessed using GRADE, and effect sizes were calculated for individual studies and illustrated using forest plots.
Sixty-three RCTs were identified. Quality of evidence ranged from high (medication; k = 29) to very low (nutrient supplementation, neurofeedback, occupational therapy; k = 1 each). Medications demonstrated consistent strong impact on ADHD symptoms and inconsistent impact on impairment. Diverse cognitive/behavioral treatments (C/BTs) demonstrated inconsistent impact on ADHD symptoms but strong and consistent impact on impairment and executive function skills, plus moderate benefits on internalizing symptoms. No interventions demonstrated significant safety concerns. Long-term maintenance (up to 3 years post-treatment) was demonstrated for C/BTs, though moderate quality of evidence was noted because participants cannot be fully blinded to receipt of treatment.
The effects of C/BTs and medication appear complementary, not duplicative. Combining medication and C/BT is advised at treatment outset to maximize engagement, maintenance, and response breadth (i.e. improving both ADHD symptoms/cognitive performance and coping skills/functional impairments). Engagement strategies (e.g. motivational interviewing) may facilitate uptake. Novel treatments do not yet demonstrate effects on ADHD symptoms or impairments in adolescents but remain a promising area for research.
注意力缺陷/多动障碍(ADHD)在青少年期表现出独特的发育特征,这对优化且适合该年龄段的治疗具有重要意义。此次为期10年的更新是一系列系统评价中的第三次,旨在研究青少年ADHD治疗的疗效和安全性。我们广泛考察了对ADHD症状、功能损害及其他报告结局的疗效。同时考虑了急性和长期疗效以及治疗调节因素。
我们在PubMed、EMBASE和PsycINFO数据库中检索了2013年至2024年发表或即将发表的文章,并结合手工检索以及本系列早期综述中确定的随机对照试验(RCT)。纳入了针对诊断为ADHD的青少年(年龄10.0 - 19.9岁)进行干预措施安全性或疗效研究的RCT。提取并审查研究特征,使用GRADE评估证据质量,计算各研究的效应量并通过森林图展示。
共识别出63项RCT。证据质量从高(药物治疗;k = 29)到极低(营养补充、神经反馈、职业治疗;各k = 1)不等。药物治疗对ADHD症状有持续的强烈影响,但对功能损害的影响不一致。多种认知/行为治疗(C/BT)对ADHD症状的影响不一致,但对功能损害和执行功能技能有强烈且一致的影响,对内化症状也有中等程度的益处。没有干预措施显示出明显的安全问题。C/BT显示出长期维持效果(治疗后长达3年),不过由于参与者无法完全对接受治疗不知情,故证据质量中等。
C/BT和药物治疗的效果似乎具有互补性,而非重复性。建议在治疗开始时将药物治疗和C/BT相结合,以最大限度地提高参与度、维持率和反应广度(即改善ADHD症状/认知表现以及应对技能/功能损害)。参与策略(如动机性访谈)可能有助于提高接受度。新型治疗方法尚未显示出对青少年ADHD症状或功能损害的效果,但仍是一个有前景的研究领域。